Reta-Peptide
Finnrick has tested 253 samples from Reta-Peptide across 14 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| MOTS-c | 8 | 6 Mar 2026 | 3 Aug 2026 | |||||
| Cagrilintide | 4 | 1 Jul 2025 | 8 May 2026 | |||||
| Ipamorelin | 16 | 24 Jul 2025 | 20 Jul 2026 | |||||
| PT-141 | 6 | 31 Aug 2025 | 15 Aug 2026 | |||||
| NAD+ | 4 | 20 Feb 2026 | 3 Aug 2026 | |||||
| Melanotan II | 5 | 4 Sep 2025 | 15 Jun 2026 | |||||
| SS-31 | 4 | 13 Mar 2026 | 12 Jun 2026 | |||||
| GHK-Cu | 27 | 16 Jul 2025 | 20 Jul 2026 | |||||
| Tirzepatide | 36 | 20 Jun 2025 | 13 Jul 2026 | |||||
| CJC-1295 | 9 | 24 Jul 2025 | 13 Jul 2026 | |||||
| BPC-157 | 18 | 16 Jul 2025 | 20 Jul 2026 | |||||
| Retatrutide | 85 | 20 Jun 2025 | 15 Aug 2026 | |||||
| TB-500 | 12 | 24 Jul 2025 | 20 Jul 2026 | |||||
| Tesamorelin | 18 | 9 Sep 2025 | 20 Jul 2026 | |||||
The Reta-Peptide samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Customer Reviews
These indicators of customer satisfaction are based on reports submitted by the public through the Finnrick testing program, and are not verified.
Based on 83 overall satisfaction reports
People who submitted test requests to Finnrick gave Reta-Peptide an average satisfaction rating of 4.6 out of 5 across 83 reports associated with samples received and tested by Finnrick. Customers rated payment methods (4.2/5) comparatively lower.
Most recent Reta-Peptide tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 15 Aug 2026 | Retatrutide | View | 5mg | 5.9mg | +18.0% | 99.60% | March 2, 2026 | No label / Silver crimp / Blue cap | Lab G | Public | |
| 15 Aug 2026 | PT-141 | View | 10mg | 10.1mg | +1.0% | 99.90% | P41 | No label / Silver crimp / Red cap | Lab G | Public | |
| 13 Aug 2026 | Retatrutide | View | 10mg | 10.5mg | +5.0% | 99.70% | Jul.02,2026 | No label / Silver crimp / Clear Blue cap | Lab G | Public | |
| 13 Aug 2026 | Retatrutide | View | 5mg | 5.1mg | +2.0% | 99.50% | January, 31; 2026 | No label / Silver crimp / Blue cap | Lab G | Public | |
| 13 Aug 2026 | Retatrutide | View | 5mg | 5.5mg | +10.0% | 99.60% | April 2, 2026 | No label / Silver crimp / Blue cap | Lab G | Public | |
| 3 Aug 2026 | MOTS-c | View | 40mg | 41.9mg | +4.8% | 98.40% | MS40 | No label / Silver crimp / Red cap | Lab E | Public | |
| 3 Aug 2026 | NAD+ | View | 500mg | 347mg | -30.6% | 98.60% | NJ500 | No label / Copper crimp / Clear cap | Lab E | Public | |
About Reta-Peptide Test Results From Finnrick
Reta-Peptide is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 14 products and 253 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud) and customer satisfaction reports with sub-scores that provide additional context. Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
Reta-Peptide Testing Activity & Score Summary
In the past 30 days, Finnrick has published 7 new test results for Reta-Peptide, and 41 in the past three months. The overall dataset includes 253 tested samples with an average score of 7.6/10 across all products.
Across 252 identity-tested samples, 96% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.8%. Approximately 95% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Retatrutide (85 tests, 99% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 0.0 to 10.0 (average 8.2/10), suggesting significant batch-to-batch differences.
- Tirzepatide (36 tests, 100% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 3.5 to 10.0 (average 7.8/10), suggesting significant batch-to-batch differences.
- GHK-Cu (27 tests, 100% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 3.9 to 10.0 (average 7.8/10), suggesting significant batch-to-batch differences.